News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. (ESPR) Announces The Appointment Of Antonio M. Gotto Jr., M.D., Dphil, As Director


1/13/2014 7:20:36 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Antonio M. Gotto Jr., M.D., DPhil as a Director of the Company. Dr. Gotto will serve as a Class II director with a term of office expiring at our 2015 annual meeting of stockholders.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES